Treatment of CD19-Positive Mixed Phenotype Acute Leukemia with Blinatumomab
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Mixed phenotype acute leukemia (MPAL) encompasses a rare group of acute leukemia with blasts expressing markers specific to several lineages, which accounts for 2-5% of all newly diagnosed cases of acute leukemia. At present, patients with MPAL are treated with acute lymphoblastic leukemia (ALL)-directed chemotherapy. However, the prognosis of MPAL, especially in cases of relapsed/refractory (R/R) disease, remains poor. Blinatumomab, a bispecific T cell-engaging antibody, has shown encouraging outcomes in R/R B cell ALL positive for CD19. Here, we report a patient with CD19+ MPAL who achieved complete remission after treatment with blinatumomab, which may be a therapeutic option for patients with relapsed CD19+ MPAL. To our knowledge, this is the first case report of MPAL treated with blinatumomab in Korea.
Abstract
Mixed phenotype acute leukemia (MPAL) encompasses a rare group of acute leukemia with blasts expressing markers specific to several lineages, which accounts for 2-5% of all newly diagnosed cases of acute leukemia. At present, patients with MPAL are treated with acute lymphoblastic leukemia (ALL)-directed chemotherapy. However, the prognosis of MPAL, especially in cases of relapsed/refractory (R/R) disease, remains poor. Blinatumomab, a bispecific T cell-engaging antibody, has shown encouraging outcomes in R/R B cell ALL positive for CD19. Here, we report a patient with CD19+ MPAL who achieved complete remission after treatment with blinatumomab, which may be a therapeutic option for patients with relapsed CD19+ MPAL. To our knowledge, this is the first case report of MPAL treated with blinatumomab in Korea.
참고문헌 (6)
- Weinberg OK, "Mixed-phenotype acute leukemia : historical overview and a new definition", Leukemia, 24, pp.1844~1851 (2010)
- Wolach O, "How I treat mixed-phenotype acute leukemia", Blood, 125, pp.2477~2485 (2015)
- Cernan M, "Mixed-phenotype acute leukemia : state-of-the-art of the diagnosis, classification and treatment", Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 161, pp.234~241 (2017)
- Ribera JM, "Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia", Expert Rev Hematol, 10, pp.1057~1067 (2017)
- Kantarjian H, "Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia", N Engl J Med, 376, pp.836~847 (2017)
- El Chaer F, "Treatment of CD19-positive mixed phenotype acute leukemia with blinatumomab", Am J Hematol, 94, pp.E7~E8 (2019)